Pharmaceutical Executive
December 30, 2017
Features
37
12
Pharm Exec details the latest approaches to combating disease and health crises on a global scale-including industry perspectives from those involved on the front lines.
December 29, 2017
Features
37
12
Amid a widening net of health threats worldwide, alliances forged in research and response may be more critical than ever to stem the tide.
December 13, 2017
From the Editor
37
12
FDA's approval of the first-ever digital medicine, while sparking legitimate concerns around ethics and trust, could signal improvements ahead to the much-chronicled woes in drug adherence and compliance.
December 12, 2017
Columns
37
12
Figuring out the right formula to address global health-for the better.
December 11, 2017
Columns
37
12
In 2017, patients gained access to the first gene therapies and more orphan and breakthrough drugs.
December 11, 2017
Features
37
12
Groundbreaking treatment approaches call for innovative commercialization strategies.
December 10, 2017
Columns
37
12
New action plan urges tighter alignment of public health policy with the development of targeted therapies.
December 10, 2017
Features
37
12
Drawing from his research roots and the leadership lessons gained in melding business and culture in geographies across the globe, Ruud Dobber is busy steering AstraZeneca’s US course as it navigates the complexities of a fast-evolving therapeutic market.
December 01, 2017
Special Sponsored Section
37
12
Despite having the tenth-largest pharma market in the world and being the birthplace of medical breakthroughs, from insulin to stem cells, Canada seems to be punching below its weight when it comes to health innovation. There are signs, however, that things may be changing as the nation looks to bulk back up.
December 01, 2017
Issue PDF
37
12
Click the title above to open the Pharmaceutical Executive December 2017 issue in an interactive PDF format.